Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in Taiwan as part of the expansion phase of its THIO-101 Phase 2 trial. The trial is focused on evaluating ateganosine (THIO) for advanced non-small cell lung cancer (NSCLC) in patients who have been heavily pre-treated and have previously failed treatment with checkpoint inhibitors and chemotherapy. This expansion marks a significant milestone, allowing access to a larger patient pool across Europe and Asia. The trial includes two treatment arms: ateganosine sequenced with cemiplimab (Libtayo®) and ateganosine monotherapy, with Regeneron supplying Libtayo for the combination cohort. As of May 15, 2025, the median overall survival for the 22 patients in the third-line treatment was reported as 17.8 months. The treatment has been generally well-tolerated. Further results from the study will be presented as the trial progresses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.